Consensus guidelines for the detection of immunogenic cell death

Oliver Kepp(Inserm), Laura Senovilla(Inserm), Ilio Vitale(National Cancer Institute), Erika Vacchelli(Inserm), Sandy Adjemian(Inserm), Patrizia Agostinis(Shanghai Cell Therapy Research Institute), Lionel Apétoh(Inserm), Fernando Aranda(Inserm), Vincenzo Barnaba(Istituto Pasteur), Norma Bloy(Inserm), Laura Bracci(Istituto Superiore di Sanità), Karine Breckpot(Cellular Research (United States)), David Brough(University of Manchester), Aitziber Buqué(Inserm), María G. Castro(University of Michigan), Mara Cirone(Sapienza University of Rome), María I. Colombo(Universidad de Ciencias Medicas), Isabelle Cremer(Inserm), Sandra Demaria(New York Proton Center), Luciana Dini(University of Salento), Aristides G. Eliopoulos(University of Crete), Alberto Faggioni(Sapienza University of Rome), Silvia C. Formenti(NYU Langone Health), Jitka Fučíková(Charles University), Lucia Gabriele(Istituto Superiore di Sanità), Udo S. Gaipl(Friedrich-Alexander-Universität Erlangen-Nürnberg), Jérôme Galon(Délégation Paris 5), Abhishek D. Garg(Shanghai Cell Therapy Research Institute), François Ghiringhelli(Inserm), Nathalia A. Giese(Heidelberg University), Zong Sheng Guo(University of Pittsburgh), Akseli Hemminki(University of Helsinki), Martin Herrmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), James W. Hodge(National Institutes of Health), Stefan Holdenrieder(University Hospital Bonn), Jamie Honeychurch(Manchester Academic Health Science Centre), Hong‐Ming Hu(Providence Portland Medical Center), Xing Huang(Inserm), Tim Illidge(Manchester Academic Health Science Centre), Koji Kono(National University of Singapore), Mladen Korbelik(BC Cancer Agency), Dmitri V. Krysko(Ghent University Hospital), Sherene Loi(Peter MacCallum Cancer Centre), Pedro R. Löwenstein(University of Michigan), Enrico Lugli(Humanitas University), Yuting Ma(Inserm), Frank Madeo(University of Graz), Angelo A. Manfredi(Vita-Salute San Raffaele University), Isabelle Martins(Université Paris-Sud), Domenico Mavilio(Humanitas University), Laurie Menger(Inserm), Nicolò Merendino(Università degli Studi della Tuscia), Michael Michaud(Inserm), Grégoire Mignot(Oniris), Karen Mossman(Infectious Disease Research Institute), Gabriele Multhoff(TUM Klinikum), Rudolf Oehler(Comprehensive Cancer Center Vienna), Fabio Palombo(Istituto Pasteur), Theocharis Panaretakis(Karolinska Institutet), Jonathan Pol(Inserm), Enrico Proietti(Istituto Superiore di Sanità), Jean‐Ehrland Ricci(Inserm), Chiara Riganti(University of Turin), Patrizia Rovere–Querini(Vita-Salute San Raffaele University), Anna Rubartelli(Azienda Ospedaliera Universitaria Policlinico "G. Martino"), Antonella Sistigu(National Cancer Institute), Mark J. Smyth(The University of Queensland), Juergen Sonnemann(Jena University Hospital), Radek Špíšek(Charles University), John Stagg(Centre Hospitalier de l’Université de Montréal), Abdul Qader Sukkurwala(Inserm), Éric Tartour(Inserm), Andrew Thorburn(The Medical Center of Aurora), Stephen H. Thorne(University of Pittsburgh), Peter Vandenabeele(Ghent University Hospital), Francesca Velotti(Università degli Studi della Tuscia), Samuel T. Workenhe(Infectious Disease Research Institute), Haining Yang(University of Hawaiʻi at Mānoa), Wei‐Xing Zong(Stony Brook University), Laurence Zitvogel(Inserm), Guido Kroemer(Délégation Paris 5), Lorenzo Galluzzi(Délégation Paris 5)
OncoImmunology
September 2, 2014
Cited by 818Open Access
Full Text

Abstract

and to screen large chemical libraries for putative ICD inducers, based on a high-content, high-throughput platform that we recently developed. Such a platform allows for the detection of multiple DAMPs, like cell surface-exposed calreticulin, extracellular ATP and high mobility group box 1 (HMGB1), and/or the processes that underlie their emission, such as endoplasmic reticulum stress, autophagy and necrotic plasma membrane permeabilization. We surmise that this technology will facilitate the development of next-generation anticancer regimens, which kill malignant cells and simultaneously convert them into a cancer-specific therapeutic vaccine.


Related Papers

No related papers found

Powered by citation graph analysis